Technical Snapshots for These Generic Drugs Stocks -- Allergan, Catalent, Tetraphase Pharma, and pSivida
30 Aug, 2017, 06:15 ET
NEW YORK, August 30, 2017 /PRNewswire/ --
If you want a Stock Review on AGN, CTLT, TTPH, or PSDV then come over to http://dailystocktracker.com/register/ and sign up for your free customized report today. The global Generic Drugs market is highly fragmented owing to the presence of large, well-established vendors in the market. The market is characterized by the presence of a vast number of local pharmaceutical companies and is densely distributed with suppliers. Pre-market today, DailyStockTracker.com monitors the most recent performances of Allergan PLC (NYSE: AGN), Catalent Inc. (NYSE: CTLT), Tetraphase Pharmaceuticals Inc. (NASDAQ: TTPH), and pSivida Corp. (NASDAQ: PSDV). Access DailyStockTracker.com's complimentary reports for today's stocks line-up at:
Shares in Dublin, Ireland headquartered Allergan PLC saw a slight drop of 0.16%, ending Tuesday's trading session at $223.58. The stock recorded a trading volume of 1.34 million shares. The Company's shares have gained 6.46% on an YTD basis. The stock is trading 2.14% below its 200-day moving average. Moreover, shares of Allergan, which develops, manufactures, markets, and distributes medical aesthetics, biosimilar, and over-the-counter pharmaceutical products worldwide, have a Relative Strength Index (RSI) of 29.07.
On August 28th, 2017, Allergan announced that The Allergan Foundation will donate $100,000 to help victims of Hurricane Harvey. The donation will be made to the American Red Cross, which has mobilized its resources to respond to the devastation caused by Hurricane Harvey in Texas and across the Gulf Coast region. Visit us today and access your complete report on AGN for free at:
Somerset, New Jersey headquartered Catalent Inc.'s stock skyrocketed 13.89%, closing the day at $40.27. A total volume of 5.61 million shares was traded, which was above their three months average volume of 993,280 shares. The Company's shares have advanced 16.05% in the past month, 13.34% in the previous three months, and 49.37% since the start of this year. The stock is trading 13.55% and 32.03% above its 50-day and 200-day moving averages, respectively. Additionally, shares of Catalent, which provides advanced delivery technologies and development solutions for drugs, biologics, and consumer health products worldwide, have an RSI of 77.71.
On August 23rd, 2017, Catalent announced that John Chiminski, Chairman and CEO, and Matthew Walsh, Executive Vice President and CFO, will present at the Morgan Stanley 15th Annual Global Healthcare Conference on September 11th, 2017, at 10:30 a.m. EDT in New York City. A live webcast of the presentation will be accessible on the Company's website. The complimentary research report on CTLT can be accessed at:
On Tuesday, shares in Watertown, Massachusetts headquartered Tetraphase Pharmaceuticals Inc. recorded a trading volume of 528,342 shares. The stock ended the day 0.15% lower at $6.71. The Company's shares have advanced 2.60% in the past month and 66.50% on an YTD basis. The stock is trading above its 200-day moving average by 7.67%. Furthermore, shares of Tetraphase Pharma, which develops various antibiotics for the treatment of serious and life-threatening multidrug-resistant infections, have an RSI of 59.06.
On August 02nd, 2017, Tetraphase Pharma reported financial results for Q2 ended June 30th, 2017. During the quarter, revenues were $1.6 million; R&D expenses were $28.5 million; G&A expenses were $5.1 million; and net loss was $31.8 million. As of June 30th, 2017, the Company had cash and cash equivalents of $118.2 million and 40.0 million shares outstanding.
On August 28th, 2017, research firm Piper Jaffray initiated an 'Overweight' rating on the Company's stock, with a target price of $14 per share. Register for free on DailyStockTracker.com and download the research report on TTPH at:
Watertown, Massachusetts headquartered pSivida Corp.'s stock dropped 3.31%, finishing yesterday's session at $1.17 with a total trading volume of 312,390 shares. The Company's shares are trading below their 50-day moving average by 16.23%. Shares of the Company, which develops sustained-release drug-delivery products for the treatment of chronic eye diseases in the US and the UK, have an RSI of 43.52. Get free access to your research report on PSDV at:
Daily Stock Tracker:
Daily Stock Tracker (DST) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. DST has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
DST has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email [email protected]. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by DST. DST is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
DST, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. DST, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, DST, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither DST nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Email: [email protected]
Phone number: (207)331-3313
Office Address: 377 Rivonia Boulevard, Rivonia, South Africa
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
Share this article